Tuesday, April 16, 2024
4/16/2024
Indiana has one of the highest rates of primary treatment admissions for heroin and opioids per capita, with significant drug overdose mortality rates and an ongoing opioid crisis in certain areas of the state. Three years ago, Indiana University (IU) Health—the largest comprehensive health system in the state—formed a statewide Behavioral Health Collaborative to address the opioid crisis and other behavioral health challenges. As part of this work, IU Health established an Addictions and Pain Management Program at its academic health center in Indianapolis. The program has been well-attended with favorable outcome indicators. The overall goal of this request is to improve access to Medication Assisted Treatment (MAT) among persons with opioid use disorder (OUD) by replicating IU Health’s successful Addictions and Pain Management Program in the IU Health West service area—an area of the state with considerable opioid misuse and limited treatment options. The comprehensive, evidence-based program includes 12 step/self-help meetings, intensive outpatient program (IOP) therapy, and MAT (focusing on naltrexone). Program completion is defined as participation in all therapy groups, attending three support groups per week, negative daily BAL, negative random urine drug screens, participation in daily physical therapy, and compliance with medication management for at least a six-week period. Over half of patients typically continue the program (on a less intense basis) after the six-week period. Specific objectives of the “Addictions and Pain Management Program at IU Health West” project are to (1) Increase the number of individuals with OUD receiving MAT from a current baseline of zero to 75 per year; (2) Increase the number of individuals with OUD receiving IOP (including MAT as necessary) from a current baseline of zero to 100 per year; (3) Facilitate program completion for at least 55% of patients admitted to the Addictions and Pain Management Program at IU Health West; (3) Decrease illicit opioid drug use and prescription opioid misuse between baseline and program completion (including an average reduction of 25% of patients reporting any past 30-day illicit drug use, 40% of patients reporting any past 30-day opioid use, and 25% of patients reporting any past 30-day injection drug use); (4) Decrease illicit opioid drug use and prescription opioid misuse at 6-month follow-up among at least 40% of program completers; and (5) Improve self-reported quality of life between baseline and program completion (specifically; at least 20% of patients will report gains in any form of employment between intake and program completion). In addition, IU Health will offer (and encourage) Hepatitis C and HIV testing to all patients.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
